4.6 Article

Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern

期刊

CELL REPORTS MEDICINE
卷 3, 期 3, 页码 -

出版社

CELL PRESS
DOI: 10.1016/j.xcrm.2022.100535

关键词

-

资金

  1. South African Medical Research Council [96825, 96838]
  2. South African Research Chairs Initiative of the Department of Science and Innovation
  3. National Research Foundation of South Africa [98341]
  4. EDCTP2 program of the European Union [TMA2016SF-1535-CaTCH-22]
  5. Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa) - Wellcome Trust [203135/Z/16/Z]
  6. Poliomyelitis Research Foundation [PRF 21/65]
  7. SAMRC
  8. MRC UK
  9. NRF
  10. Lily and Ernst Hausmann Trust
  11. L'Oreal/Unesco Women in Science South Africa
  12. Department of Science and Technology
  13. National Research Foundation

向作者/读者索取更多资源

This study confirms that neutralizing and binding antibody responses to Ad26.COV2.S vaccination remain stable for 6 months and show significant boost in individuals with breakthrough infections. These findings have important implications for population immunity in areas where the Ad26.COV2.S vaccine has been widely administered.
The Janssen (Johnson & Johnson) Ad26.COV2.S non-replicating viral vector vaccine has been widely deployed for COVID-19 vaccination programs in resource-limited settings. Here we confirm that neutralizing and binding antibody responses to Ad26.COV2.S vaccination are stable for 6 months post-vaccination, when tested against multiple SARS-CoV-2 variants. Secondly, using longitudinal samples from individuals who experienced clinically mild breakthrough infections 4 to 5 months after vaccination, we show dramatically boosted binding antibodies, Fc effector function, and neutralization. These high titer responses are of similar magnitude to humoral immune responses measured in convalescent donors who had been hospitalized with severe illness, and are cross-reactive against diverse SARS-CoV-2 variants, including the neutralization resistant Omicron (B.1.1.529) variant that currently dominates global infections, as well as SARS-CoV-1. These data have implications for population immunity in areas where the Ad26.COV2.S vaccine has been widely deployed, but where ongoing infections continue to occur at high levels.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据